Today: 28 February 2026
Subscribe
Browse Category

NASDAQ:QURE 24 September 2025 - 16 December 2025

uniQure (QURE) Stock Jumps in Pre-Market on Dec. 16, 2025: FDA AMT-130 Uncertainty, Analyst Price Targets, and Key Catalysts Ahead

uniQure (QURE) Stock Jumps in Pre-Market on Dec. 16, 2025: FDA AMT-130 Uncertainty, Analyst Price Targets, and Key Catalysts Ahead

uniQure shares jumped about 15% to $23.50 in pre-market trading Dec. 16 after a 10% after-hours gain, despite ongoing FDA uncertainty over its Huntington’s disease gene therapy, AMT-130. The FDA told uniQure its Phase I/II data are “currently unlikely” to support a Biologics License Application, prompting the company to seek further talks in early 2026.
16 December 2025
··
UniQure’s Roller-Coaster: Gene Therapy Breakthrough, FDA Setback, and What’s Next for QURE Stock

UniQure Stock Plunges 50% on FDA Shocker – What’s Next for QURE’s Gene Therapy Ambitions?

uniQure shares plunged over 50% after the FDA said data for its Huntington’s disease gene therapy is not sufficient for approval, reversing earlier guidance. The stock dropped from about $68 to $34, wiping out roughly half its market value. Analysts called it a major regulatory setback, with some cutting price targets. Shareholder rights law firms launched investigations following the 57% one-day decline.
4 November 2025
·
UniQure’s Roller-Coaster: Gene Therapy Breakthrough, FDA Setback, and What’s Next for QURE Stock

UniQure’s Roller-Coaster: Gene Therapy Breakthrough, FDA Setback, and What’s Next for QURE Stock

UniQure shares plunged nearly 65% to $23–24 midday Nov. 3 after the FDA ruled current Huntington’s trial data insufficient for approval, erasing billions in market value. The company had raised $345 million in September at $47.50/share following a surge on positive trial results. Q2 revenue was $5.3 million, with a net loss of $37.7 million. Cash reserves rose to about $550 million after the equity raise.
3 November 2025
··
uniQure (QURE) Stock Soars on Huntington’s Breakthrough – Key Facts & 2025 Outlook

A One‑Time Brain Gene Therapy Just Slowed Huntington’s by 75%—Is This the Turning Point Families Have Waited For?

Early trial data show AMT-130 gene therapy slowed Huntington’s disease progression by 75% at 36 months in high-dose patients compared to controls. Treated participants’ neurofilament light levels dropped below baseline. The neurosurgical procedure lasts 12–20 hours. The developer plans a U.S. regulatory filing in 2026 if results hold.
26 September 2025
·
uniQure (QURE) Stock Soars on Huntington’s Breakthrough – Key Facts & 2025 Outlook

Gene Therapy Breakthrough: uniQure’s QURE Stock Skyrockets on Huntington’s Triumph

uniQure shares jumped over 150% on September 24, 2025, after its Huntington’s gene therapy slowed disease progression by 75% in a landmark trial. The company’s market value rose above $2.5 billion. uniQure plans to seek FDA approval in early 2026 and secured a $175 million credit facility to support commercialization. Cash reserves reached $377 million as of June 30, 2025.
24 September 2025
····
uniQure (QURE) Stock Soars on Huntington’s Breakthrough – Key Facts & 2025 Outlook

uniQure (QURE) Stock Soars on Huntington’s Breakthrough – Key Facts & 2025 Outlook

uniQure reported its gene therapy AMT-130 slowed Huntington’s disease progression by 75% over three years in high-dose patients. Trading in QURE shares was halted on volatility; the stock jumped from $4.45 to the mid-teens. The company secured a $175 million loan to fund AMT-130’s potential launch. Wall Street analysts rate the stock “Buy,” with targets averaging $37–$40.
24 September 2025
···
Go toTop